Oxidative Stress is an Important Cause of Parkinson's Disease Clinical Trial
Official title:
A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Idebenone in the Treatment of Early-stage Parkinson's Disease With Motor and Non-motor Symptoms
On May 30,2018 ,Investigators intend to conduct a multicenter, randomized, double-blind, placebo-controlled study of idebenone in the treatment of early-stage Parkinson's disease with motor and non-motor symptoms which is to observe the therapeutic effect of idebenone on motor symptoms and non-motor symptoms in patients with early Parkinson's disease。
This clinical trail was a multicenter, parallel, randomized, double-blind, placebo-controlled
study led by Professor Liu Chunfeng from the Second Affiliated Hospital of Suzhou University
which consisted of 15 sub-centers with a total of 180 subjects.
This clinical study is divided into two phases:
The first stage: double-blind period, 24 weeks. Three queues containing idebenone 180
mg/d,360 mg/d and placebo.
The second stage: open label extension period, 24 weeks. All enrolled participants continued
to take idebenone 180 mg/d to study the long-term effects of idebenone.
;